Spineart Gains FDA Clearance for PERLA TL Robotic Use
Geneva, Switzerland , Aug 26, 2026 Spineart and eCential Robotics have announced that the U.S. Food and Drug Administration...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Geneva, Switzerland , Aug 26, 2026 Spineart and eCential Robotics have announced that the U.S. Food and Drug Administration...
COPENHAGEN, Denmark and NEW YORK, June 10, 2026 HERVolution Therapeutics has announced compelling preclinical proof-of-concept data demonstrating the potential...
LONDON, United Kingdom, June 8, 2026 Smith+Nephew has announced the successful completion of the first clinical procedures using its...
